Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Whole blood mRNA transcription profiling of host immune changes in neonatal sepsis during vancomycin therapy


ABSTRACT: The purpose of this study was to investigate changes in host gene expression profiles of neonatal infants with sepsis prior to the initiation of and during vancomycin therapy, to identify treatment-responsive genes and signature pathways associated with recovery from neonatal sepsis. The study analyzed data from a subset of 35 infants recruited to the NeoVanc trial, a multi-center randomized open label phase IIb study which compared the efficacy, safety and pharmacokinetics of an optimized dosing to a standard dosing regimen of vancomycin in neonates and infants aged less than 90 days with late onset bacterial sepsis (ClinicalTrials.gov ID: NCT02790996). All infants selected had a positive blood culture for Staphylococcus epidermidis in addition to a clinical diagnosis of neonatal sepsis. Whole blood samples were collected for each infant at five time points between the time of randomization to the trial until a short term follow up visit, approximately 30 days after randomization.

ORGANISM(S): Homo sapiens

SUBMITTER: Edward Parkinson 

PROVIDER: E-MTAB-15687 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial.

Hill Louise F LF   Turner Mark A MA   Lutsar Irja I   Heath Paul T PT   Hardy Pollyanna P   Linsell Louise L   Jacqz-Aigrain Evelyne E   Roilides Emmanuel E   Sharland Mike M  

Trials 20200415 1


<h4>Background</h4>Vancomycin has been used in clinical practice for over 50 years; however, validated, pharmacokinetic (PK) data relating clinical outcomes to different dosing regimens in neonates are lacking. Coagulase negative staphylococci (CoNS) are the most commonly isolated organisms in neonatal, late-onset sepsis (LOS). Optimised use to maximise efficacy while minimising toxicity and resistance selection is imperative to ensure vancomycin's continued efficacy.<h4>Methods</h4>NeoVanc is a  ...[more]

Similar Datasets

2016-05-29 | E-MTAB-4785 | biostudies-arrayexpress
2024-06-13 | PXD046061 | Pride
2025-03-02 | E-MTAB-14798 | biostudies-arrayexpress
2016-07-15 | E-GEOD-76003 | biostudies-arrayexpress
2025-02-03 | E-MTAB-14713 | biostudies-arrayexpress
2018-03-05 | PXD004082 | Pride
2020-10-30 | E-MTAB-9642 | biostudies-arrayexpress
2017-05-01 | E-MTAB-5274 | biostudies-arrayexpress
2017-05-01 | E-MTAB-5273 | biostudies-arrayexpress
2024-10-27 | E-MTAB-14506 | biostudies-arrayexpress